Autism Spectrum Disorder Diagnostics Market Report 2024

The autism spectrum disorder diagnosis market size has grown strongly in recent years. It will grow from $25.54 billion in 2023 to $27.39 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be credited to heightened awareness and recognition of Autism Spectrum Disorder (ASD), expansion of diagnostic criteria, advancements in diagnostic tools, improvements in the healthcare system, and public health campaigns.

The autism spectrum disorder diagnosis market size is expected to see strong growth in the next few years. It will grow to $36.35 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. Anticipated growth in the forecast period is driven by the rising prevalence of autism spectrum disorder, increased awareness, and early screening initiatives. There is also a focus on precision medicine and biomarkers. Key trends expected during this period include ongoing development of innovative technologies, heightened attention to adult diagnosis, growing demand for point-of-care testing, integration of artificial intelligence (AI) and machine learning, and an upsurge in research activities.

The expansion of specialized diagnostic centers is anticipated to drive growth in the autism spectrum disorders diagnostic market. These centers, staffed by healthcare professionals, psychologists, and specialists, conduct thorough evaluations to diagnose autism spectrum disorder. The proliferation of these centers can be attributed to advancements in diagnostics, increased demand for comprehensive care, professional training, research initiatives, and the recognition of autism as a significant public health concern. Specialized diagnostic centers are pivotal in improving diagnostic precision, supporting early intervention, and improving outcomes for individuals with ASD. They offer specialized expertise, advanced diagnostic tools, comprehensive assessments, personalized treatment plans, family support, and opportunities for research collaboration. For example, Autism Speaks reported an increase in autism care network sites from 20 to 25 across North America between 2021 and 2022, underscoring the role of specialized centers in expanding the autism spectrum disorders diagnostic market.

Leading companies in the autism spectrum disorder diagnostics market are developing AI-powered platforms to enhance early and accurate diagnosis. These platforms analyze behavioral patterns, genetic data, and neuroimaging results to improve early detection, personalize risk assessment, and provide decision support for clinicians. For instance, Cognoa Inc., a US-based technology company specializing in pediatric behavioral health solutions, received FDA approval in June 2021 for Canvas Dx, an AI-based autism diagnosis aid. Canvas Dx aims to enhance diagnostic accuracy, tailor treatment plans, and improve patient outcomes through advanced analytics and data-driven insights.

In March 2024, Fletch Equity LLC, a private equity firm based in the US, completed the acquisition of Autism Spectrum Interventions (ASI) for an undisclosed sum. This acquisition is intended to support ASI's growth strategy, enhancing its presence in California and potentially extending into adjacent states. ASI, based in the US, specializes in providing applied behavior analysis (ABA) therapy services tailored for children diagnosed with autism spectrum disorder (ASD).

Major companies operating in the autism spectrum disorder diagnostics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Siemens Healthineers, Quest Diagnostics Incorporated, Agilent Technologies Inc., Otsuka Pharmaceutical Co. Ltd., ARUP Laboratories, Invitae Corporation, Ambry Genetics, Cortica Inc., GeneDx, Cognoa Inc., Axial Therapeutics Inc., Curemark, EarliTec Diagnostics Inc., Yamo Pharmaceuticals.

Asia-Pacific was the largest region in the autism spectrum disorder diagnostics market in 2023. The regions covered in the autism spectrum disorder diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the autism spectrum disorder diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Autism spectrum disorder (ASD) diagnostics encompass a variety of methods and tools employed to identify and evaluate individuals suspected of having ASD. The objective of these diagnostics is to precisely detect the presence and severity of ASD symptoms, facilitate early intervention, and inform personalized treatment plans. Conducted by healthcare professionals specializing in neurodevelopmental disorders, these assessments are crucial for delivering timely support and services to individuals on the autism spectrum and their families.

Within the autism spectrum disorder diagnostics market, key categories include autistic disorder, Asperger syndrome, pervasive developmental disorder (PDD), and others. Autistic disorder is characterized by challenges in social interaction, communication, and repetitive behaviors. Available services encompass behavioral approaches, early intervention, medication, and others, with distribution channels including hospital pharmacies, drug stores, retail pharmacies, and online platforms.

The autism spectrum disorder diagnostics market research report is one of a series of new reports that provides autism spectrum disorder diagnostics market statistics, including the autism spectrum disorder diagnostics industry global market size, regional shares, competitors with autism spectrum disorder diagnostics market share, detailed autism spectrum disorder diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the autism spectrum disorder diagnostics industry. These autism spectrum disorder diagnostics market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autism spectrum disorder (ASD) diagnostics market consists of revenues earned by entities by providing services such as behavioral assessments, genetic testing, speech and language evaluations, and psychological assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. The autism spectrum disorder (ASD) diagnostics market also includes sales of diagnostic tests and kits, neuroimaging equipment, and behavioral assessment tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.